PetVivo (NASDAQ:PETV) Trading 1.1% Higher

Posted by Michael Baxter on Jun 29th, 2024

PetVivo Holdings, Inc. (NASDAQ:PETV – Get Free Report)’s share price was up 1.1% during mid-day trading on Wednesday . The company traded as high as $0.46 and last traded at $0.46. Approximately 23,653 shares changed hands during trading, a decline of 44% from the average daily volume of 42,518 shares. The stock had previously closed at $0.45.

PetVivo Stock Performance

The stock has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.93. The firm has a market capitalization of $10.33 million, a P/E ratio of -0.60 and a beta of 2.24. The company has a current ratio of 0.90, a quick ratio of 0.62 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling at PetVivo

In other news, CEO John Lai purchased 150,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the purchase, the chief executive officer now directly owns 1,288,592 shares in the company, valued at approximately $773,155.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PetVivo stock. Warberg Asset Management LLC acquired a new stake in shares of PetVivo Holdings, Inc. (NASDAQ:PETV – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 27,693 shares of the company’s stock, valued at approximately $29,000. Warberg Asset Management LLC owned 0.19% of PetVivo at the end of the most recent quarter. 24.55% of the stock is currently owned by institutional investors.

PetVivo Company Profile

(Get Free Report)

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.